The company Linnea SA has been licensed by Swissmedic for the production of THC active pharmaceutical ingredients (APIs) with a high THC content.
Linnea SA was awarded a narcotics license from Swissmedic at the end of 2022, making it one of the first companies in Switzerland to manufacture and export high-THC products. The company, which has more than 40 years of experience in the pharmaceutical industry, will begin manufacturing GMP certified active pharmaceutical ingredients in 2023.
Medicinal cannabis products
Now the question GMP certified pharmaceutical grade cannabis larger than ever, Linnea hopes to meet the needs of customers and patients around the world with this license. “We are so honored to have been awarded a narcotics license in Switzerland. This opens up many new commercial opportunities for Linnea Cannabinoids and our customers,” said Susanne Caspar, CEO of Linnea SA.
“High-quality cannabinoid ingredients are essential to producing the pharmaceuticals patients need, and we are eager to contribute our expertise to this effort. We look forward to the opportunities this presents us as we create new partnerships and continue to innovate in the industry.”
Source: businesscann.com (EN)